Taldefgrobep Alfa in Adults With Overweight and Obesity
Public ClinicalTrials.gov record NCT07281495. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep Alfa in Adults Living With Overweight and Obesity
Study identification
- NCT ID
- NCT07281495
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Taldefgrobep Alfa Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 23, 2025
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
- Last update posted
- Mar 19, 2026
2025 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site-001 | Chula Vista | California | 91911 | — |
| Site-014 | Montclair | California | 97163 | — |
| Site-011 | Sacramento | California | 95821 | — |
| Site-018 | Tustin | California | 92780 | — |
| Site-020 | Orlando | Florida | 32804 | — |
| Site-008 | Palm Springs | Florida | 33461 | — |
| Site-015 | St. Petersburg | Florida | 33704 | — |
| Site-007 | Chicago | Illinois | 60625 | — |
| Site-016 | Indianapolis | Indiana | 46254 | — |
| Site-010 | Baton Rouge | Louisiana | 70808 | — |
| Site-009 | Metairie | Louisiana | 70006 | — |
| Site-006 | City of Saint Peters | Missouri | 63303 | — |
| Site-003 | Springfield | Missouri | 65807 | — |
| Site-019 | Monroe | North Carolina | 28112 | — |
| Site-002 | Fargo | North Dakota | 58104 | — |
| Site-017 | North Charleston | South Carolina | 29405 | — |
| Site-005 | Austin | Texas | 78745 | — |
| Site-012 | McKinney | Texas | 75069 | — |
| Site-013 | San Antonio | Texas | 78229 | — |
| Site-004 | Arlington | Virginia | 22205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07281495, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07281495 live on ClinicalTrials.gov.